Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells

Pharmaceutical Research

Volumn 27, Issue 8, 2010, Pages 1703-1712

  Tompkins, Leslie ^a   Lynch, Caitlin ^a   Haidar, Sam ^b   Polli, James ^a   Wang, Hongbing ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CYP3A4; excipients; induction; PXR; repression

Indexed keywords

CALCIUM PHOSPHATE DIBASIC; CITRIC ACID; CROSCARMELLOSE SODIUM; CROSPOVIDONE; CYTOCHROME P450 3A4; DODECYL SULFATE SODIUM; EXCIPIENT; FUMARIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; LUCIFERASE; MACROGOL 3350; MAGNESIUM STEARATE; MALIC ACID; MESSENGER RNA; MICROCRYSTALLINE CELLULOSE; POLYSORBATE 80; PREGNANE X RECEPTOR; SILICON DIOXIDE; STARCH; STARCH GLYCOLATE SODIUM; SUCROSE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ARTICLE; CELL STRAIN HEPG2; COLON; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; INTESTINE CELL; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; WESTERN BLOTTING; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

COLON; CYTOCHROME P-450 CYP3A; EXCIPIENTS; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; IMMUNOBLOTTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955469924     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0170-2     Document Type: Article

References (42)

1. FDA. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. CDER, Guidance for Industry. 2000.
2. EMEA. Note for guidance on the investigation of bioavailability and bioequivalence. Committee for Proprietary Medicinal Products. 2001.
3. JE Polli LX Yu JA Cook GL Amidon RT Borchardt BA Burnside, et al. 2004 Summary workshop report: biopharmaceutics classification system-implementation challenges and extension opportunities J Pharm Sci 93 1375 81 10.1002/jps.20064 15124197 (Pubitemid 38725012)
4. JE Polli BS Abrahamsson LX Yu GL Amidon JM Baldoni JA Cook, et al. 2008 Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond AAPS J 10 373 9 10.1208/s12248-008-9040-9 18679807
5. LX Yu GL Amidon JE Polli H Zhao MU Mehta DP Conner, et al. 2002 Biopharmaceutics classification system: the scientific basis for biowaiver extensions Pharm Res 19 921 5 10.1023/A:1016473601633 12180542 (Pubitemid 34804232)
6. LZ Benet GL Amidon DM Barends H Lennernas JE Polli VP Shah, et al. 2008 The use of BDDCS in classifying the permeability of marketed drugs Pharm Res 25 483 8 10.1007/s11095-007-9523-x 18236138
7. EMEA. Guideline on the investigation of bioequivalence. Committee for Medicinal Products for Human Use. 2008.
8. KM Koch AF Parr JJ Tomlinson EP Sandefer GA Digenis KH Donn, et al. 1993 Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time Pharm Res 10 1027 30 10.1023/A:1018918907670 8397394 (Pubitemid 23211427)
9. DA Adkin SS Davis RA Sparrow PD Huckle IR Wilding 1995 The effect of mannitol on the oral bioavailability of cimetidine J Pharm Sci 84 1405 9 10.1002/jps.2600841205 8748321
10. CY Wuand LZ Benet 2005 Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm Res 22 11 23 10.1007/s11095-004-9004-4 (Pubitemid 40558141)
11. CD Klaassen AL Slitt 2005 Regulation of hepatic transporters by xenobiotic receptors Curr Drug Metab 6 309 28 10.2174/1389200054633826 16101571 (Pubitemid 41086765)
12. UA Meyer 1996 Overview of enzymes of drug metabolism J Pharmacokinet Biopharm 24 449 59 10.1007/BF02353473 9131484 (Pubitemid 27156931)
13. JH Lin 2000 Sense and nonsense in the prediction of drug-drug interactions Curr Drug Metab 1 305 31 10.2174/1389200003338947 11465042
14. H Wang EL LeCluyse 2003 Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes Clin Pharmacokinet 42 1331 57 10.2165/00003088-200342150-00003 14674787 (Pubitemid 38045840)
15. K Sachs-Barrable A Thamboo SD Lee KM Wasan 2007 Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells J Pharm Pharm Sci 10 319 31 17727795
16. CA Barta K Sachs-Barrable F Feng KM Wasan 2008 Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers Mol Pharm 5 863 75 10.1021/mp800050q 18651749
17. GN Kumar S Surapaneni 2001 Role of drug metabolism in drug discovery and development Med Res Rev 21 397 411 10.1002/med.1016 11579440 (Pubitemid 32751462)
18. H Wang LM Tompkins 2008 CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme Curr Drug Metab 9 598 610 10.2174/138920008785821710 18781911
19. SA Kliewer JT Moore L Wade JL Staudinger MA Watson SA Jones, et al. 1998 An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway Cell 92 73 82 10.1016/S0092-8674(00)80900-9 9489701 (Pubitemid 28053299)
20. JM Lehmann DD McKee MA Watson TM Willson JT Moore SA Kliewer 1998 The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions J Clin Investig 102 1016 23 10.1172/JCI3703 9727070
21. EL LeCluyse E Alexandre GA Hamilton C Viollon-Abadie DJ Coon S Jolley, et al. 2005 Isolation and culture of primary human hepatocytes Methods Mol Biol (Clifton, NJ) 290 207 29
22. L Li T Chen JD Stanton T Sueyoshi M Negishi H Wang 2008 The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline- carboxamide is a novel antagonist of human constitutive androstane receptor Mol Pharmacol 74 443 53 10.1124/mol.108.046656 18492798
23. SR Faucette T Sueyoshi CM Smith M Negishi EL Lecluyse H Wang 2006 Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor J Pharmacol Exp Ther 317 1200 9 10.1124/jpet.105.098160 16513849 (Pubitemid 43764125)
24. H Wang S Faucette T Sueyoshi R Moore S Ferguson M Negishi, et al. 2003 A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression J Biol Chem 278 14146 52 10.1074/jbc.M212482200 12571232 (Pubitemid 36799961)
25. L Li JD Stanton AH Tolson Y Luo H Wang 2009 Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways Pharm Res 26 872 82 10.1007/s11095-008-9788-8 19034627
26. YS Habib LL Augsburger RF Shangraw 2002 Production of inert cushioning beads: effect of excipients on the physicomechanical properties of freeze-dried beads containing microcrystalline cellulose produced by extrusion-spheronization Int J Pharm 233 67 83 10.1016/S0378-5173(01)00924-3 11897412 (Pubitemid 34230420)
27. RF Shangraw 1997 Emerging trends in the use of pharmaceutical excipients Pharm Technol 21 36 42
28. GA Digenis TB Gold VP Shah 1994 Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance J Pharm Sci 83 915 21 10.1002/jps.2600830702 7965669 (Pubitemid 24228538)
29. A Fetzner S Bohm S Schreder R Schubert 2004 Degradation of raw or film-incorporated beta-cyclodextrin by enzymes and colonic bacteria Eur J Pharm Biopharm 58 91 7 10.1016/j.ejpb.2004.02.001 15207542 (Pubitemid 38781009)
30. T Yamagata H Kusuhara M Morishita K Takayama H Benameur Y Sugiyama 2007 Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients Drug Metab Dispos 35 1142 8 10.1124/dmd.106.014217 17446265 (Pubitemid 46956435)
31. T Yamagata M Morishita H Kusuhara K Takayama H Benameur Y Sugiyama 2009 Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients Int J Pharm 370 216 9 10.1016/j.ijpharm.2008.12.005 19118611
32. G Luo M Cunningham S Kim T Burn J Lin M Sinz, et al. 2002 CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes Drug Metab Dispos 30 795 804 10.1124/dmd.30.7.795 12065438 (Pubitemid 34671092)
33. FDA. In vitro evaluation of CYP induction. FDA Guidelines. 2006.
34. O Burk I Koch J Raucy E Hustert M Eichelbaum J Brockmoller, et al. 2004 The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR) J Biol Chem 279 38379 85 10.1074/jbc.M404949200 15252010 (Pubitemid 39295987)
35. H Glaeser S Drescher M Eichelbaum MF Fromm 2005 Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes Br J Clin Pharmacol 59 199 206 10.1111/j.1365-2125.2004.02265.x 15676042 (Pubitemid 40208856)
36. Rane Y, Mashru R, Sankalia M, Sankalia J. Effect of hydrophilic swellable polymers on dissolution enhancement of carbamazepine solid dispersions studied using response surface methodology. AAPS PharmSciTech. 8:Article 27. 2007.
37. BD Rege JP Kao JE Polli 2002 Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur J Pharm Sci 16 237 46 10.1016/S0928-0987(02)00055-6 12208453
38. BD Rege LX Yu AS Hussain JE Polli 2001 Effect of common excipients on Caco-2 transport of low-permeability drugs J Pharm Sci 90 1776 86 10.1002/jps.1127 11745735 (Pubitemid 33062598)
39. AE Aitken ET Morgan 2007 Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes Drug Metab Dispos 35 1687 93 10.1124/dmd.107.015511 17576808 (Pubitemid 47296065)
40. X Gu S Ke D Liu T Sheng PE Thomas AB Rabson, et al. 2006 Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents J Biol Chem 281 17882 9 10.1074/jbc.M601302200 16608838 (Pubitemid 44035587)
41. AE Aitken CM Lee ET Morgan 2008 Roles of nitric oxide in inflammatory downregulation of human cytochromes P450 Free Radic Biol Med 44 1161 8 10.1016/j.freeradbiomed.2007.12.010 18206661
42. SR Pondugula H Dong T Chen 2009 Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression Expert Opin Drug Metab Toxicol 5 861 73 10.1517/17425250903012360 19505191